EXACT Therapeutics: Positive second safety read-out from the Phase 2 ENACT trial in pancreatic cancer
• Trial Monitoring Committee has issued a positive conclusion for the pre-planned safety read-out for the increased dose (60 µl/kg), and the trial proceeds with the increased dose. • This safety read-out triggers opening of the full enrolment at all sites. • Interim efficacy read-out is expected around end-2026.
Oslo, Norway, 26 June 2026. Reference is made to the private placement of EXACT Therapeutics AS ("EXACT-Tx" or the "Company", Euronext Growth ticker: EXTX), a clinical-stage precision medicine company, is pleased to announce that the Trial Monitoring Committee (“TMC”) for the Phase 2 ENACT trial in first line locally advanced pancreatic cancer (NCT06850623) has unanimously issued a positive conclusion for the safety read-out following the per-protocol review of the second safety cohort enrolled in the trial and recommended to proceed with the trial using the 60 µl/kg dose.
The TMC has reviewed the safety data from the second safety cohort with three subjects with locally advanced pancreatic cancer treated with the Company’s proprietary PS101 drug candidate at a dose of 60 µl/kg body weight in combination with modified FOLFIRINOX and completing the 28-day safety window. Based on the second safety cohort data, TMC recommends proceeding with the trial at a PS101 dose of 60 µl/kg and the ENACT trial is now open for unrestricted patient enrolment.
All ten hospital sites are open for enrolment, and the interim efficacy read-out is expected around end-2026.
Information in this announcement is considered inside information pursuant to EU Market Abuse Regulation (MAR) and subject to the disclosure requirements pursuant to MAR Article 17 and Section 5-12 of the Norwegian Securities Trading Act. This stock exchange announcement was published by John M. Edminson, CFO, on 08:10 (CET) 26 June 2026.
About EXACT Therapeutics: EXACT Therapeutics is a clinical-stage precision medicine company utilizing the power of ultrasound to activate the proprietary drug PS101 and enhance the clinical benefit of oncology therapies. PS101 has a unique mode of action and may be combined with a wide range of therapeutic agents within oncology and across a multitude of other indications, including brain diseases. EXACT Therapeutics’ shares are traded on Euronext Growth Oslo (EXTX). Further information may be found here: www.exact-tx.com
For further information, please contact: Per Walday CEO EXACT Therapeutics Email: per.walday@exact-tx.com
Forward looking statements: This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by this forward-looking statement.